The Food and Drug Administration (FDA) announced it will finish its safety review of the abortion medication mifepristone by March 2024, following a court-mandated report. The review includes a comparison of mifepristone’s safety profile to surgical abortions within the first 10 weeks of pregnancy, analyzing data from around 100,000 women who used the drug.
Results are anticipated by mid-December, with the final report expected in March, which could impact ongoing legal and regulatory debates surrounding access to abortion pills. Mifepristone was approved by the FDA in 2000 and has been considered safe and effective based on extensive peer-reviewed research.
Its dispensing requirements were eased in 2021 and finalized in 2023, though the agency plans to reassess these changes based on new safety data, input from patients and healthcare providers, and additional studies. This review is occurring amid legal challenges, including a Louisiana-led lawsuit seeking to reinstate in-person dispensing requirements, and debates about telehealth provisions that have been instrumental in maintaining abortion access since the overturn of Roe v.
Wade. The review was prompted by political and legal pressures, including claims from conservative groups about potential increased risks, though expert consensus indicates mifepristone’s adverse effects are less than 0.5%.
The FDA’s decision comes as the agency faces scrutiny under President Trump’s pick to lead the FDA, Dr. Heidi Overton, who has expressed opposition to medication abortion. The outcome of this review could influence ongoing legal battles and future abortion policies nationwide.
The Food and Drug Administration (FDA) announced it will finish its safety review of the abortion medication mifepristone by March 2024, following a court-mandated report. The review includes a comparison of mifepristone’s safety profile to surgical abortions within the first 10 weeks of pregnancy, analyzing data from around 100,000 women who used the drug.
Results are anticipated by mid-December, with the final report expected in March, which could impact ongoing legal and regulatory debates surrounding access to abortion pills. Mifepristone was approved by the FDA in 2000 and has been considered safe and effective based on extensive peer-reviewed research.
Its dispensing requirements were eased in 2021 and finalized in 2023, though the agency plans to reassess these changes based on new safety data, input from patients and healthcare providers, and additional studies. This review is occurring amid legal challenges, including a Louisiana-led lawsuit seeking to reinstate in-person dispensing requirements, and debates about telehealth provisions that have been instrumental in maintaining abortion access since the overturn of Roe v.
Wade. The review was prompted by political and legal pressures, including claims from conservative groups about potential increased risks, though expert consensus indicates mifepristone’s adverse effects are less than 0.5%.
The FDA’s decision comes as the agency faces scrutiny under President Trump’s pick to lead the FDA, Dr. Heidi Overton, who has expressed opposition to medication abortion. The outcome of this review could influence ongoing legal battles and future abortion policies nationwide.